Liver
Clonazepam R H O C C H A Flurazepam Diazepam Chlordiazepoxide Chlorazepate Halazepam Oxazepam Lorazepam Temazepam Prazepam Triazolam Alprazolam 50–100hours hours50 hours15 hours10 hours0
Glucuronide form
(the final pathway for excretion, by the kidney) 2-Keto 3-Hydroxy Subgroup of benzodiazepines Triazolo Others
Average half-time (T1/2) for
the compound/s listed directly above the red arrow
Enzymatic reaction: Acetylation A C H O R Conjugation Hydroxylation Oxidation Reduction
Legend
References
1. Gorman JM, Kent JM, Sullivan GM et al. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000; 157: 4; 493–505.
2. Liebowitz MR, Gorman JM, Fyer AJ et al. Lactate provocation of panic attacks, II: biochemical and physiological findings. Arch Gen Psychiatry 1985; 42: 709–712.
3. Gorman JM, Fyer MR, Goetz R et al.
Ventilatory physiology of patients with panic disorder. Arch Gen Psychiatry 1988; 45: 31–39.
4. Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1984; 41: 751–763.
5. Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 1989; 28: 295–306.
6. Klein E, Zohar J, Geraci MF et al. Anxiogenic effect of m-CPP in patients with panic
disorder: comparison to caffeine’s anxiogenic effect. Biol Psychiatry 1991; 30: 973–984. 7. Pyke RE, Greenberg HS. Norepinephrine
challenges in panic patients. J Clin Psychopharmacol 1986; 6: 279–285. 8. Veltman DJ, van Zijderverld GA, van Dyck R.
Epinephrine infusion in panic disorder: a double-blind placebo-controlled study. J Affect Disord 1996; 39: 139–140. 9. Jensen CF, Peskind ER, Veith CR et al.
Hypertonic saline infusion induces panic in patients with panic disorder. Biol Psychiatry 1991; 30: 628–630.
10. Bradwejn J, Koszycki D. The cholecystokinin hypothesis of anxiety and panic disorder. Ann NY Acad Sci 1994; 713: 273–282. 11. Tork I, Hornung J-P. Raphe nuclei and the
serotonergic system. In: The Human
Nervous System (Paxinos G, ed). San Diego: Academic Press, 1990: 1001–1022.
12. Aston-Jones G, Akaoka H, Charlety P et al. Serotonin selectively attenuates glutamate- evoked activation of noradrenergic locus ceruleus neurons. J Neurosci 1991; 11: 760–769.
13. Deakin JFW, Graeff F. 5-HT and mechanism of defense. J Psychopharmacol 1991; 5: 305–315.
14. Brady LS, Gold PW, Herkenham M et al. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA
corticotropin-releasing factor and
vasopressin either intraventricularly or into the amygdala on aggressive and investigate behaviour in the rat. Regul Pept 1990; 28: 199–214.
16. Butler PD, Weiss JM, Stout JC et al. Corticotropin-releasing factor produces fear-enhancing and behavioural activating effects following infusion into the locus ceruleus. J Neurosci 1990; 10: 176–183. 17. Cannistraro PA, Rauch SL. Neural circuitry of
anxiety: evidence from structural and functional neuroimaging studies. Psychopharmacol Bull 2003; 37: 8–25. 18. Tiihonen J, Kuikka J, Rasanen P et al.
Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol Psychiatry 1997; 2: 463–471.
19. Gorman JM. New molecular targets for antianxiety interventions. J Clin Psychiatry 2003; 64 (Suppl 3).
20. Rickels K, Bielski RJ, Feltner DE et al. Efficacy and safety of pregabalin and alprazolam in generalized anxiety disorder. In: New Research Abstracts of the 155th Annual Meeting of the American Psychiatric
Association, May 21, 2002, Philadelphia, PA: Abst NR162: 44.
21. Kasper S, Blagden M, Seghers S et al. A placebo-controlled study of pregabalin and venlafaxine treatment of GAD. In: New Research Abstracts of the 155th Annual Meeting of the American Psychiatric
Association, May 21, 2002, Philadelphia, PA: Abst NR202: 55.
22. Malizia AL, Cunningham VJ, Bell CJ et al. Decreased brain GABAA–benzodiazepine
receptor in binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998; 55: 715–720.
23 Goddard AW, Mason GF, Almai A et al. Reductions in occipital cortex GABA levels in panic disorder detected with H-magnetic resonance spectroscopy. Arch Gen Psychiatry 2001; 58: 556–561.
24. Bremmer JD, Innis RB, Southwick SM et al. Decreased benzodiazepine receptor bonding in prefrontal cortex in combat- related posttraumatic stress disorder. Am J Psychiatry 2000; 157: 1120–1126.
25. Bremmer JD, Innis RB, White T et al. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 2000; 47: 96–106.
26. Borman J. The ‘ABC’ of GABA receptors. Trends Pharmacol Sci 2000; 21: 16–19. 27. Kerr DIB, Ong J. GABA receptors.
clinical syndromes and their treatment. Br J Biomed Sci 2001; 58: 111–121.
29. Rudolph U, Crestani F, Benke D et al.
Benzodiazepine actions mediated by specific c-aminobutyric acid-A receptor subtypes. Nature 1999; 401: 796–800.
30. Low K, Crestani F, Keist R et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000; 290: 131–134.
31. Zorilla EP, Koob GH. The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 2004; 13: 799–828.
32. Homes A, Heilig M, Rupniak NM et al. Neuropeptides systems as novel therapeutic targets for depression and anxiety
disorders. Trends Pharmacol Sci 2003; 24: 580–588.
33. Dubrovsky BO. Steroids, neuroactive steroids and neurosteroids in
psychopathology. Prog
Neuropsychopharmacol Biol Psychiatry 2005; 29: 169–192.
34. Monti JM, Monti D. Histamine H1receptor
antagonists in the treatment of insomnia. Is there a rational basis for use? CNS Drugs 2000; 13; 87–96.
35. Pollard H, Bouthenet ML. Autoradiographic visualization of the three histamine receptor subtypes in the brain. In: The Histamine Receptor (Schwartz JC, Haas HL, eds). New York: Wiley-Liss, 1992: 179–192.
36. Dringenberg HC, Vanderwolf CH.
Involvement of direct and indirect pathways in electrocorticographic activation. Neurosci Biobehav Rev 1998; 22: 243–257.
37. Lader M, Scotto JC. A multicentre double blind comparison of hydroxyzine, buspirone and placebo in patients with generalized and anxiety disorder. Psychopharmacology- Berl 1998; 139: 402–406.
38. Schwinghammer TL, Kroboth FJ, Juhl RP. Extrapyramidal reaction secondary to oral promethazine. Clin Pharm 1984; 3: 83–85. 39. Eison MS. Azapirones: mechanism of action
in anxiety and depression. Drug Ther 1990; 20(Suppl): 3–8.
40. De Montigny C, Blier P. Potentiation of 5-HT neurotransmission by short-term lithium: in vivo electrotransmission studies. Clin Neuropharmacol 1992; 15: 610A–611A. 41. Eison AS, Temple DL. Buspirone: review of
its pharmacology and current perspectives on its mechanism of action. Am J Med 1986; 80: 1–9.
42. Norden MJ. Buspirone treatment of sexual
buspirone. Am J Med 1986; 80(Suppl 3B): 17–21.
44. Craven J, Sutherland A. Buspirone for anxiety disorders in patients with severe lung disease. Lancet 1991; 338: 249. 45. Rapaport DM, Greenberg HE, Goldring RM.
Differing effects of the anxiolytic agents buspirone and diazepam on control of breathing. Clin Pharmacol Ther 1991; 49–401.
46. Boulenger J, Squillance K, Simon P et al. Buspirone and diazepam: comparison of subjective, psychomotor, and biological effects. Neuropsychology 1989; 22: 83–89. 47. Schaffler K, Klauznitzer W. Placebo-
controlled study on acute and subacute effects of buspirone versus bromazepam utilizing psychomotor and cognitive assessments in healthy volunteers. Pharmacopsychiatry 1989; 22: 26–33. 48. Moskowitz H, Smiley A. Effects of chronically
administered buspirone and diazepam on driving related skills performance. J Clin Psychiatry 1982; 43: 45–55.
49. Van Laar MW, Volkerts ER, van Willgenburg AP. Therapeutic effects and effects on actual driving performance of chronically
administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol 1992; 12: 86–95.
50. Lucki I, Rickels K, Giesecke A et al.
Differential effects of the anxiolytic drugs, diazepam and buspirone on memory function. Br J Clin Pharmacol 1987; 23: 207–211.
51. Boulenger J-P, Gram LF, Jolicoeur FB et al. Repeated administration of buspirone: absence of pharmacodynamic or
pharmacokinetic interaction with triazolam. Hum Psychopharmacol 1993; 8: 117. 52. Buch AB, Van Harker DR, Seidehamel RJ et
al. A study of pharmacokinetic interaction between buspirone and alprazolam at steady state. J Clin Pharmacol 1993; 33: 1104–1109.
53. Erwin CW, Linnoila M, Hartwell J et al. Effects of buspirone and diazepam, alone and in combination with alcohol, on skilled performance and evoked
potentials. J Clin Psychopharmacol 1986; 6: 199–209.
54. Rickels K, Schweizer E, Csanalosi I et al. Long term treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988; 45: 444–450.
56. Davidson JR, Dupont RL, Hedges D et al. Efficacy, safety and tolerability of venlafaxine extended release and buspirone in
outpatients with generalized anxiety disorder. J Clin Psychiatry 1999; 60: 528–529.
57. Enkelmann R. Alprazolam vs. buspirone in the treatment of outpatients with
generalized anxiety disorder.
Psychopharmacology 1991; 105: 428–432. 58. Pecknold JC, Matas M, Howarth BG et al.
Evaluation of buspirone as an antianxiety agent: buspirone and diazepam vs. placebo. Am J Psychiatry 1989; 34: 766–771.
59. Nutt D, Rickels K, Stein DJ. Generalized
Anxiety Disorder. Symptomatology, Pathogenesis and Management. London: Martin Dunitz, 2002.
60. Micallef J, Blin O. Neurobiology and clinical pharmacology of obsessive compulsive disorder. Clin Neuropharmacol 2001; 24: 191–207.
61. Cannistraro PA, Rauch SL. Neural circuitry of anxiety: evidence from structural and functional neuroimaging studies.
Psychopharmacol Bull 2003; 37(4): 8–25. 62. Zohar J, Mueller EA, Insel TR et al.
Serotonergic responsivity in OCD:
comparison of patients and healthy controls. Arch Gen Psychiatry 1987; 44: 946–951.